Frequently Asked Questions
The market is segmented based on , By Vector Type (Viral Vector and Non-Viral Vector), Method (Ex-Vivo and In-Vivo), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, and Others), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others) – Industry Trends and Forecast to 2031.
.
The Global Gene Therapy Market size was valued at USD 8.68 USD Billion in 2023.
The Global Gene Therapy Market is projected to grow at a CAGR of 18.3% during the forecast period of 2024 to 2031.
The major players operating in the market include Novartis AG, Gilead Sciences , uniQure NV, Oxford Biomedica PLC, Spark Therapeutics , SIBONO, bluebird bio , Shanghai Sunway Biotech Co. , Biogen, Dendreon Pharmaceuticals LLC, Amgen , AnGes , Enzyvant Therapeutics GmbH, Epeius Biotechnologies Corp., Astellas Pharma , American Gene Technologies, BioMarin,.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
